Welcome to ViraTherapeutics

Viruses designed for cancer therapy


ViraTherapeutics develops highly potent anti-cancer therapeutics based on oncolytic (cancer-destroying) viruses. Our proprietary oncolytic virus, VSV-GP, efficiently destroys cancer cells, while leaving normal tissues unharmed. ViraTherapeutics currently performs preclinical safety and efficacy studies for VSV-GP and aims to conduct first clinical trials in cancer patients in 2017.

Druckversion Druckversion | Sitemap
© ViraTherapeutics GmbH